SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is currently a major talking point after its recent earnings report, which, despite showing subscriber growth and exceeding revenue expectations, led to a notable sell-off. Community discussion is split between those viewing the price dip as an overreaction and a long-term buying opportunity, and those concerned about the cautious forward guidance, valuation, and the strategic implications of the potential Warner Bros. Discovery acquisition.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending as reports indicate the U.S. government is establishing a new digital asset reserve to hold seized Bitcoin, shifting from prior selling policies and removing market pressure. This comes amidst heightened market volatility, which many in the community attribute to political rhetoric and broader macroeconomic concerns. Investor sentiment remains sharply divided, with intense debate around Bitcoin's role as a digital safe haven compared to traditional assets like gold and silver, while closely watching key technical support levels.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending significantly after Chairman Ryan Cohen increased his stake by purchasing an additional 500,000 shares, which the community views as a powerful signal of confidence. This insider move has ignited fervent speculation about upcoming strategic developments, further reinforced by the stock's notable resilience and positive performance even on days when the broader market is declining.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending amidst discussions surrounding President Trump's escalating rhetoric on acquiring Greenland, which includes threats of tariffs against opposing nations. This has sparked concerns over US government finances and international relations, with some European entities reportedly divesting from US Treasuries. Community sentiment is deeply divided, with many anticipating further market volatility and a potential "Sell America" trend, while others view the current downturn as an overreaction and a "buy the dip" opportunity.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending lower as market sentiment reacts sharply to former President Trump's threats of new tariffs against European allies concerning Greenland. This has ignited a lively debate within the community, with some anticipating a deeper market correction amid broader bond market jitters, while others expect a "buy the dip" rebound, confident in the underlying strength of the tech sector despite geopolitical noise.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN Limited is seeing significant investor attention driven by its strategic pivot from Bitcoin mining to becoming a leading AI cloud infrastructure provider. The company's substantial power capacity and recent $9.7 billion Microsoft GPU cloud contract position it as a critical player in meeting the surging demand for AI compute. Community chatter highlights optimism for further hyperscaler partnerships and long-term growth, with many viewing IREN as undervalued despite market fluctuations.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Holdings Inc

Ondas Holdings is trending following a recent investor day that revealed significantly raised revenue targets and a substantial increase in backlog, prompting multiple analyst upgrades with considerably higher price targets. The community is buzzing about Ondas's strategic pivot to autonomous defense infrastructure, with many asserting the market has yet to fully price in its combat-proven technology and robust financial position. Investors are closely monitoring the integration of acquired assets and potential for major contract announcements in the rapidly evolving drone and counter-drone sectors.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is actively trending following its announced proposed public offering of common stock and warrants, which comes on the heels of an earlier surge driven by positive Phase 1 clinical trial data for its atopic dermatitis drug. The community is sharply divided, with many debating potential dilution and a subsequent price correction, while others view the offering as a strategic capital raise to advance a promising pipeline in a large market. This highlights the inherent tension for clinical-stage biotechs, balancing funding needs with encouraging early-stage therapeutic developments.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF ($DIA) is trending amidst heightened market uncertainty driven by recent tariff threats related to international trade and escalating geopolitical tensions. Community discussions are focused on the potential for increased volatility and the broader implications of global instability on established market leaders, with some anticipating significant market corrections while others look for buying opportunities.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

Newegg Commerce is trending as significant insider share accumulation has reportedly locked up much of its free float, coinciding with rising demand for PC components and AI hardware. The community is intensely discussing perceived aggressive short-seller tactics and "phantom shares" that appear to be suppressing the price on remarkably low volume. This situation is fueling strong investor convictions who anticipate an eventual, explosive short squeeze.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cathie Wood, Founder & CEO, Ark Invest, speaks during the second day of the FII PRIORITY Summit

Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD

ARK doubles down on a CRISPR bet as Intellia Therapeutics’ stock heads for its best week since October.

Equity

ARK doubles down on a CRISPR bet as Intellia Therapeutics’ stock heads for its best week since October.


A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena. (Photo by Sarah Reingewirtz/MediaNews Group/Los Angeles Daily News via Getty Images)

Nano-Cap Regentis Biomaterials Stock Is Up Nearly 15% This Year: Why Retail Traders Are Swarming It

Heading to close this week as its best week since IPO, RGNT has become a retail favorite with surging followers on Stocktwits.

MLTX Stock Erases Most Of 2025 Loses As Wall Street, Retail Bets On FDA Feedback For Sonelokimab

The FDA said that the drug, which treats a chronic inflammatory skin disorder, could establish evidence without additional trials.

Currency and Exchange Stock Chart for Finance and Economy Display. (Image Courtesy: Getty Images)

TG Therapeutics Stock Pops As Briumvi Boom Reignites Bull Case: Goldman Sachs Sees Room For 32% Rally

Strong 2026 guidance and accelerating uptake of its MS drug send TGTX to its best session in months, with Wall Street and retail piling in.

<ul class="summary-bullets"><li>The company sees 2025 revenue of $616 million compared to the analysts’ consensus estimate of $606.03 million, according to Fiscal AI data.</li><li>BRIUMVI’s U.S. net product revenue expected to reach around $182 million in Q4 and $594 million in 2025.&nbsp;</li><li>TG Therapeutics stock rallies 9% higher in Wednesday’s premarket.&nbsp;</li></ul><p>TG Therapeutics, Inc. (TGTX) drew increased attention on Wednesday, with the stock seeing a 195% increase in retail chatter on Stocktwits over the last 24 hours following the company’s ambitious revenue outlook.&nbsp;</p><p>On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.</p><h2 class="st-heading-2">What Did Stocktwits Users Say?&nbsp;</h2><p><a href="https://stocktwits.com/symbol/TGTX">TG Therapeutics stock</a> traded over 9% higher in Wednesday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;</p><figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_14_083034_png_390ef2e760.webp" alt="TGTX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 14, 2026 | Source: Stocktwits" width="933" height="108"><figcaption>TGTX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 14, 2026 | Source: Stocktwits</figcaption></figure><p>A Stocktwits user sounded optimistic about BRIUMVI achieving blockbuster status.</p><p><stembedurl>https://stocktwits.com/knowthyself/message/641747123</stembedurl></p><p>Another bullish user said the company’s ramp-up from Q3 to Q4 was impressive.&nbsp;</p><p><stembedurl>https://stocktwits.com/Uncle_Baby_Billy/message/641752748</stembedurl></p><h2 class="st-heading-2">Outlook Highlights&nbsp;</h2><p>TG Therapeutics expects BRIUMVI’s U.S. net product revenue to reach around $182 million in Q4 and $594 million for the full year of 2025. Global revenue for the year is estimated at $616 million compared to the analysts’ consensus estimate of $606.03 million, according to Fiscal AI data.&nbsp;</p><p>Looking ahead, the company anticipates total global revenue between $875 million and $900 million for 2026, with U.S. BRIUMVI sales projected at $825 million to $850 million.</p><p>BRIUMVI is a glycoengineered monoclonal antibody that targets CD20-expressing B-cells, a proven approach for treating autoimmune diseases like relapsing multiple sclerosis (RMS). By removing specific sugar molecules, BRIUMVI enhances B-cell depletion at lower doses.</p><h2 class="st-heading-2">Upcoming Clinical Milestones</h2><p>The company also teased three major milestones for 2026.&nbsp;TG Therapeutics plans to release pivotal topline data for the ENHANCE trial, which evaluates Day 1 and Day 15 intravenous doses of BRIUMVI, by mid-2026. Preliminary Phase 1 data for azer-cel in Progressive multiple sclerosis (MS) will be shared in the latter half of the year.&nbsp;</p><p>Pivotal topline results for subcutaneous BRIUMVI are expected by year-end 2026 or early 2027.&nbsp;</p><p>TGTX stock has declined by over 6% in the last 12 months.&nbsp;</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-nrxp-stock-surge-pre-market-today/cmULXc2R4eL">Why Did NRXP Stock Surge 21% Pre-Market Today?</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Biology lab technician removes a freeze-dried sample from a container in a laboratory.

Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter?

On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.

December Jobs Data Put Focus on These Sector ETFs & Stocks

December jobs data highlight sector shifts as healthcare and restaurants add jobs, while retail lags. ETFs XLV, EATZ in focus.

<ul class="summary-bullets"><li>The outlook for Q4 and FY2025 exceeds the analyst consensus estimate of $24.95 million and $84.65 million, respectively, according to Fiscal AI data.&nbsp;</li><li>Biodesix said revenue gains were largely fueled by the company’s lung diagnostics segment.</li><li>Test volumes climbed to 18,000 in Q4 and 62,600 for the year.</li></ul><p>Biodesix Inc. (BDSX) stock surged over 23% in Monday’s premarket after the Colorado-based diagnostics firm provided a strong outlook for the fourth quarter (Q4) and fiscal year 2025.&nbsp;</p><p>The company expects Q4 revenue of $28.8 million, a 41% year-over-year (YoY) increase, while full-year revenue is estimated at $88.5 million, up 24% YoY. The outlook for Q4 and FY2025 exceeds the analyst consensus estimate of $24.95 million and $84.65 million, respectively, according to Fiscal AI data.&nbsp;</p><h2 class="st-heading-2">Growth Driven By Lung Diagnostics</h2><p>Biodesix said revenue gains were largely fueled by the company’s lung diagnostics segment, which is estimated to have generated $25.2 million in Q4 and $79.2 million for the full year. The results reflect a 47% and 22% YoY increase, respectively.&nbsp;</p><p>Test volumes climbed to 18,000 in Q4 and 62,600 for the year, rising 23% and 15% from the previous year. The increase was driven by higher test volumes, stronger revenue per test, and about $1 million in collections from older claims.&nbsp;</p><blockquote><p>“Biodesix finished 2025 with a strong fourth quarter, delivering full year estimated revenue of $88.5 million, exceeding the top end of our increased guidance of $84-$86 million.”</p><p>-Scott Hutton, CEO, Biodesix</p></blockquote><p>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/BDSX">Biodesix stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;</p><figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_12_084117_png_27b632f1b5.webp" alt="BDSX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 12, 2026 | Source: Stocktwits" width="931" height="98"><figcaption>BDSX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 12, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Development Services&nbsp;</h2><p>The company’s development services segment contributed an estimated $3.6 million in Q4 and $9.3 million for 2025, representing growth of 13% and 41% over the prior year, respectively.&nbsp;</p><p>“Based on our strong revenue flow-through and operating leverage, we are affirming our expectation of positive Adjusted EBITDA in the fourth quarter,” added Hutton.&nbsp;</p><p>Biodesix said it ended 2025 with $19.0 million in cash and cash equivalents, a 14% increase over the previous quarter.&nbsp;</p><p>BDSX stock declined by over 77% in the last 12 months.&nbsp;</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-captures-20-of-global-smartphone-market/cmU96DMR4E4">Apple Captures 20% Of Global Smartphone Market, But Rising Memory Costs Cast Shadow On 2026 Growth</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Biodesix logo is seen displayed on a smartphone screen.

BDSX Stock Shot Up 23% Pre-Market Today — What’s Fueling The Surge? 

The company expects Q4 revenue of $28.8 million, a 41% year-over-year increase, while full-year revenue is estimated at $88.5 million, up 24% year-over-year.

This Diagnostics Stock Is Surging 23% Pre-Market Today – Here’s Why 

Betting on a Boom: 3 Healthcare ETFs for 2026 and Beyond

After a late-2025 rebound eased policy fears, healthcare ETFs like IXJ are gaining attention as investors position for a sector comeback in 2026.

<ul class="summary-bullets"><li>Booth said timing drove sharply different investor outcomes in Ventyx.</li><li>Clear Street said Lilly was a logical buyer and cut Ventyx to ‘Hold’.</li><li>LifeSci Capital said the stock reset to ‘Market Perform’ after the deal.</li></ul><p>Ventyx’s path through public markets culminated in a $1.2 billion buyout by&nbsp;Eli Lilly, highlighting how timing drove investor outcomes, ranging from deep drawdowns to more than 2,000% upside.</p><p>That contrast was captured by Atlas Venture partner Bruce Booth,&nbsp;an early-stage biotech venture capitalist who&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/LifeSciVC/status/2009081510192914652">said on X</a>&nbsp;that the stock’s history has become a case study in how biotech returns can be dictated less by belief and more by when investors&nbsp;choose to step in.</p><h2 class="st-heading-2"><strong>Bottom Buyers Reaped The Gains</strong></h2><p>Booth said investors who bought Ventyx shares near the lows in early 2025 would have seen gains of more than 2,000% by the time the company agreed to be acquired. He added that investors who bought at the IPO ultimately got most of their money back, which he described as a win, given that the stock had been more than 90% underwater a year earlier.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260108_095534478_png_dfe989a876.webp" alt="koyfin_20260108_095534478.png" width="2400" height="1240"></figure><h2 class="st-heading-2"><strong>From Early Optimism To Strategic Reset</strong></h2><p>When Ventyx went public, its main drug program targeted TYK2, a protein involved in immune system signaling that is linked to autoimmune and inflammatory diseases. Over time, the company pivoted toward the NLRP3 inflammasome, reshaping its pipeline to focus on inflammatory, cardiometabolic, and neurodegenerative diseases.</p><p>That strategic reset proved critical. Lilly said the acquisition&nbsp;strengthened its position in cardiometabolic health, immunology, and neuroscience, while filling a gap in NLRP3 assets that could pair with its existing therapies.</p><p>Clear Street, which downgraded Ventyx to ‘Hold’ from ‘Buy’ following the deal, described Lilly as a “logical” buyer, noting that Ventyx’s inflammasome-focused portfolio complements Lilly’s franchises and addresses an area where Lilly previously lacked assets.&nbsp;</p><h2 class="st-heading-2"><strong>Clinical Data Sustained Interest Through&nbsp;</strong></h2><p>Despite extreme share price swings, Ventyx continued to generate clinical updates that kept its science in focus. In June, the company reported positive Phase 2a results for VTX3232 in early Parkinson’s disease. The study showed that the drug was safe and well-tolerated, reached the brain as intended, and reduced key inflammation-related biomarkers, indicating that it engaged its intended target.</p><p>VTX3232 targets NLRP3, a protein involved in driving inflammation in neurodegenerative diseases. In January 2025, H.C. Wainwright described Ventyx’s Phase 2 pipeline as high risk/high reward, citing both the potential of this inflammation-focused approach and the long history of difficulty in developing effective treatments for neurodegenerative disorders.</p><h2 class="st-heading-2"><strong>Wall Street Reframes After The Buyout</strong></h2><p>With the acquisition agreement in place, analysts moved to align ratings with the deal terms. LifeSci Capital downgraded Ventyx to ‘Market Perform’ from ‘Outperform’, setting a $14 price target after the company agreed to be acquired. Clear Street made a similar move, cutting the stock to ‘Hold’ from ‘Buy’ while raising its target from $11 to $14.</p><p>By contrast, UBS initiated coverage with a ‘Buy’ rating on Tuesday, citing improving biotech fundamentals, a recovering risk appetite, and Ventyx’s pipeline as among several small- and mid-cap biotech stories positioned for stronger performance in 2026.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment for Ventyx was ‘extremely bullish’ amid ‘extremely high’ message volume.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/vtyx_ss_png_0e1eef59df.webp" alt="vtyx ss.png" width="969" height="141"><figcaption>VTYX sentiment and message volume as of January 7| Source: Stocktwits</figcaption></figure><p><a href="https://stocktwits.com/symbol/VTYX">Ventyx’s stock</a> has surged 467% over the past 12 months.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Ventyx’s stock (VTYX) has surged 467% over the past 12 months. (Representative Image: Getty Images)

Ventyx’s $1.2B Buyout By Eli Lilly Proves Timing Often Beats Conviction In Biotech Investing — A VC Explains

Bottom buyers saw over 2,000% gains, while IPO investors merely broke even after a 90% drawdown, according to Atlas Venture’s Bruce Booth.

Bank of America shares S&P 500 warning for 2026

The stock market's under duress, but Wall Street's biggest banks feel it's still pretty expensive. Bank of America warns that theS&P 500 is priced for perfection as we progress deeper into 2026...

SSgA Active Trust - State Street Health Care Select Sector SPDR ETF

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

XLV
Health Care Select Sector SPDR Fund

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest XLV News

XLVHealth Care Select Sector SPDR Fund